echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > ESMO Live Direct Strike Double Free or Triple? Choice of combination therapy regimens for Merkel cell carcinoma

    ESMO Live Direct Strike Double Free or Triple? Choice of combination therapy regimens for Merkel cell carcinoma

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    preface

    The 2022 Annual Meeting of the European Society of Oncology (ESMO) will be held



    Merkel cell carcinoma is an aggressive cutaneous malignancy associated




    This multicenter Phase 2 randomized study included patients with unresectable, recurrent, or metastatic Merkel cell carcinoma who received navulijumab 240 mg IV q2 wks + ipilimumab 1 mg/kg IV q6 wks (Arm A) or navuliumab 240 mg IV q2 wks + ipicumab 1 mg/kg IV q6 wks + SBRT on a 1:1 scale (24Gy, group B)




    A total of 50 patients (24 without ICI and 26 had received ICI), 25 received navuliyuzumab + ipicizumab, and 25 patients received navuliyumab + ipicimumab + SBRT (median follow-up time of 14.




    The ORR is 100% (95% CI, 82% to 100%) in patients with ICI and a complete response (CR) rate is 41%.




    The study showed that the first-line treatment of patients with advanced Merkel cell carcinoma with navulijumab + ipicumab reached 100%, the response was long-lasting and safe, and it also showed clinical activity



    References:

    1.
    S.
    Kim,et al.
    Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma.
    2022 ESMO.
    Abstract LBA42.

    Editing/Typography: Jiang Zhou

    Execution: Small garden

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.